Maria del Carmen Asensio-Lopez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria del Carmen Asensio-Lopez has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Lax
Biomedical Research Institute Virgen de la Arrixaca, University of Murcia, Murcia, Spain
5 shared publications Domingo Pascual-Figal
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publicationsFernando Soler
Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla and University of Murcia, Ctra. Madrid-Cartagena S/N, Murcia, Spain
3 shared publicationsJose Javier Fuster
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
3 shared publicationsSilvia Pascual-Oliver
Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla and University of Murcia, Ctra. Madrid-Cartagena S/N, Murcia, Spain
3 shared publicationsFrancisco Jose Bastida-Nicolas
Instituto Murciano de Investigación Biosanitaria (IMIB) Pascual Parrilla and University of Murcia, Ctra. Madrid-Cartagena S/N, Murcia, Spain
2 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Correction: AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
- 4 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1)
Open AccessCorrection: AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
- Open Access
- 14 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10002
miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology and cardiovascular disease. miR-106b-5p, a member of the miR-106b-25 cluster, has been widely studied for its oncogenic activity in various malignancies. However, its role as a direct molecular driver of anthracycline-induced cardiotoxicity has only recently been uncovered. This finding highlights new therapeutic possibilities at the intersection of oncology and cardiovascular medicine. This review outlines the dual role of miR-106b-5p as a key modulator in both tumor progression and chemotherapy-induced cardiac dysfunction. miR-106b-5p is upregulated in numerous cancers—including breast, prostate, lung, gastric, colorectal, hepatocellular, and esophageal—and promotes tumorigenesis via suppression of tumor suppressors such as PTEN, BTG3, p21, and SMAD7, leading to activation of oncogenic pathways like PI3K/AKT and TGF-β. Importantly, we present the first evidence that miR-106b-5p is significantly upregulated in the myocardium in response to doxorubicin treatment, where it drives left ventricular dysfunction by targeting PR55α, a key regulator of PP2A activity. This pathway results in cytoplasmic HDAC4 accumulation, aberrant activation of the YY1 transcription factor, and upregulation of sST2, a biomarker linked to adverse cardiac remodeling and poor prognosis. In response, we developed AM106, a novel locked nucleic acid antagomir that silences miR-106 b-5p. Preclinical studies demonstrate that AM106 restores PR55α/PP2A activity, reduces sST2 expression, and prevents structural and functional cardiac damage without compromising anti-tumor efficacy. In parallel, artificial intelligence (AI) tools could be leveraged in the future—based on established AI applications in miRNA cancer research—to accelerate the identification of miR-106b-5p-related biomarkers and guide personalized therapy selection. Our findings position miR-106b-5p as a previously unrecognized molecular bridge between cancer and doxorubicin-induced cardiotoxicity. The development of the AM106 antagomir represents a promising approach with potential clinical applicability in cardio-oncology, offering dual benefits: tumor control and cardioprotection. Coupling this innovation with AI-driven analysis of patient data may enable precision risk stratification, early intervention, and improved outcomes. miR-106b-5p thus emerges as a central therapeutic target and biomarker candidate for transforming the clinical management of cancer patients at risk for heart failure.
- 14 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10002
Open AccessmiR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation
MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology and cardiovascular disease. miR-106b-5p, a member of the miR-106b-25 cluster, has been widely studied for its oncogenic activity in various malignancies. However, its role as a direct molecular driver of anthracycline-induced cardiotoxicity has only recently been uncovered. This finding highlights new therapeutic possibilities at the intersection of oncology and cardiovascular medicine. This review outlines the dual role of miR-106b-5p as a key modulator in both tumor progression and chemotherapy-induced cardiac dysfunction. miR-106b-5p is upregulated in numerous cancers—including breast, prostate, lung, gastric, colorectal, hepatocellular, and esophageal—and promotes tumorigenesis via suppression of tumor suppressors such as PTEN, BTG3, p21, and SMAD7, leading to activation of oncogenic pathways like PI3K/AKT and TGF-β. Importantly, we present the first evidence that miR-106b-5p is significantly upregulated in the myocardium in response to doxorubicin treatment, where it drives left ventricular dysfunction by targeting PR55α, a key regulator of PP2A activity. This pathway results in cytoplasmic HDAC4 accumulation, aberrant activation of the YY1 transcription factor, and upregulation of sST2, a biomarker linked to adverse cardiac remodeling and poor prognosis. In response, we developed AM106, a novel locked nucleic acid antagomir that silences miR-106 b-5p. Preclinical studies demonstrate that AM106 restores PR55α/PP2A activity, reduces sST2 expression, and prevents structural and functional cardiac damage without compromising anti-tumor efficacy. In parallel, artificial intelligence (AI) tools could be leveraged in the future—based on established AI applications in miRNA cancer research—to accelerate the identification of miR-106b-5p-related biomarkers and guide personalized therapy selection. Our findings position miR-106b-5p as a previously unrecognized molecular bridge between cancer and doxorubicin-induced cardiotoxicity. The development of the AM106 antagomir represents a promising approach with potential clinical applicability in cardio-oncology, offering dual benefits: tumor control and cardioprotection. Coupling this innovation with AI-driven analysis of patient data may enable precision risk stratification, early intervention, and improved outcomes. miR-106b-5p thus emerges as a central therapeutic target and biomarker candidate for transforming the clinical management of cancer patients at risk for heart failure.
- Open Access
- 15 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
Background: The causal relationship between the activation of nuclear factor erythroid 2-related factor 2 (NRF2) and the preservation of SERCA2a function in mitigating myocardial ischemia–reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. This study aims to unravel how NRF2 directly or indirectly influences SERCA2a function and its regulators, phospholamban (PLN) and Dwarf Open Reading Frame (DWORF), by testing the pharmacological repositioning of AEOL-10150 (AEOL) in the context of mI/R injury. Methods: C57BL6/J, Nrf2 knockout ( Nrf2 −/− ), and wild-type ( Nrf2 + / + ) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. Results: In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2 −/− mice and in Nrf2 / Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Conclusions: Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- 15 May 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
Open AccessAEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury
Background: The causal relationship between the activation of nuclear factor erythroid 2-related factor 2 (NRF2) and the preservation of SERCA2a function in mitigating myocardial ischemia–reperfusion (mI/R) injury, along with the associated regulatory mechanisms, remains incompletely understood. This study aims to unravel how NRF2 directly or indirectly influences SERCA2a function and its regulators, phospholamban (PLN) and Dwarf Open Reading Frame (DWORF), by testing the pharmacological repositioning of AEOL-10150 (AEOL) in the context of mI/R injury. Methods: C57BL6/J, Nrf2 knockout ( Nrf2 −/− ), and wild-type ( Nrf2 + / + ) mice, as well as human induced pluripotent stem cell-derived cardiomyocytes (hiPSCMs) were subjected to I/R injury. Gain/loss of function techniques, RT-qPCR, western blotting, LC/MS/MS, and fluorescence spectroscopy were utilized. Cardiac dimensions and function were assessed by echocardiography. Results: In the early stages of mI/R injury, AEOL administration reduced mitochondrial ROS production, decreased myocardial infarct size, and improved cardiac function. These effects were due to NRF2 activation, leading to the overexpression of the micro-peptide DWORF, consequently enhancing SERCA2a activity. The cardioprotective effect induced by AEOL was diminished in Nrf2 −/− mice and in Nrf2 / Dworf knockdown models in hiPSCMs subjected to simulated I/R injury. Our data show that AEOL-induced NRF2-mediated upregulation of DWORF disrupts the phospholamban-SERCA2a interaction, leading to enhanced SERCA2a activation and improved cardiac function. Conclusions: Taken together, our study reveals that AEOL-induced NRF2-mediated overexpression of DWORF enhances myocardial function through the activation of the SERCA2a offering promising therapeutic avenues for mI/R injury.
- Open Access
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1607362
Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
Heart failure with reduced ejection fraction (HFrEF) remains a significant global health concern, characterized by high rates of morbidity, mortality, and frequent hospitalizations. Despite substantial progress in medical therapies over the past decades, the clinical course of HFrEF is often progressive, necessitating continuous research into novel and refined therapeutic strategies to improve patient outcomes. The management of HFrEF is a dynamic field, with clinical practice guidelines undergoing regular updates to incorporate the latest evidence and emerging treatment approaches. This constant evolution underscores the importance of ongoing investigation and the need for healthcare professionals to remain informed about the newest advancements in this area. The research topic "Advanced Therapeutic Strategies and Safety Profiles in Heart Failure with Reduced Ejection Fraction," published in Frontiers in Pharmacology, serves as a valuable platform for the dissemination of cutting-edge research focused on enhancing the treatment and safety profiles for individuals living with HFrEF. This topic encompasses a wide range of investigations, including the application of artificial intelligence and machine learning for predicting therapeutic outcomes, detailed evaluations of drug efficacy and safety across diverse patient populations, comparative studies of different treatment strategies, clinical trials exploring novel pharmacological agents, and the integration of advanced diagnostic tools to personalize treatment responses. This editorial aims to critically analyze and contextualize three specific studies recently published within this research topic, integrating their findings with the current understanding of HFrEF management up to the year 2025.By examining these recent contributions, this editorial seeks to provide an expert perspective on their significance and potential impact on the evolving landscape of HFrEF therapy.The cornerstone of contemporary HFrEF management lies in the implementation of guideline-directed medical therapy (GDMT), which has demonstrably improved survival and reduced hospitalizations (Heidenreich et al., 2022;Carrizales-Sepúlveda et al., 2024;Beghini et al., 2025). This foundational approach is built upon the synergistic effects of four main classes of medications: Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), which are often preferred as first-line renin-angiotensin system inhibitors due to their superior efficacy compared to ACE inhibitors or angiotensin receptor blockers; betablockers, which play a crucial role in mitigating the detrimental effects of the sympathetic nervous system; mineralocorticoid receptor antagonists (MRAs), which help to counteract the effects of aldosterone; and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is), which have emerged as a transformative therapy demonstrating significant benefits in reducing heart failure hospitalizations and cardiovascular mortality across a broad range of patients with and without diabetes. Current guidelines increasingly emphasize the importance of initiating and rapidly up-titrating these four foundational therapies to their maximally tolerated doses within the first few months following diagnosis to achieve optimal clinical outcomes. Major guideline updates, such as the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the 2023 ESC Focused Update of the 2021 ESC Guidelines, have further refined the recommendations for HFrEF management (Heidenreich et al., 2022). Notably, these updates highlight the expanded role of SGLT2 inhibitors across the entire spectrum of left ventricular ejection fraction, signifying a significant shift in the therapeutic paradigm (Carrizales-Sepúlveda et al., 2024).Beyond these foundational therapies, other emerging strategies and considerations have gained prominence in the management of HFrEF up to 2025 (Beghini et al., 2025).Vericiguat, an oral soluble guanylate cyclase stimulator, is recommended for consideration in patients with worsening HFrEF despite optimal GDMT, based on the findings of the VICTORIA trial (PW et al., 2020). Intravenous iron supplementation is increasingly recognized for its benefits in symptomatic patients with HFrEF and iron deficiency, improving symptoms and quality of life and potentially reducing heart failure hospitalizations (Beghini et al., 2025). Furthermore, the integration of palliative care into the management of advanced heart failure is gaining increasing recognition as a crucial component for improving patient quality of life and addressing their individual goals of care (Carrizales-Sepúlveda et al., 2024). The 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction further reinforces the central role of the "four pillars" of GDMT, emphasizing the preferred use of ARNIs as the initial renin-angiotensin system inhibitor in eligible patients. In this updated pathway, ACE inhibitors and angiotensin receptor blockers are primarily considered in patients who have contraindications, intolerance, or limited access to ARNIs (Maddox et al., 2024).Within the Frontiers in pharmacology, three recent studies offer valuable insights into advanced therapeutic strategies and safety profiles in HFrEF. Study 1: Vericiguat in Post-Acute Heart Failure (Li et al., 2025). This retrospective, singlecenter study sought to evaluate the safety and efficacy of vericiguat in 100 patients hospitalized for acute heart failure (HF) who were subsequently followed up as outpatients for a median of 68 days (Li et al., 2025). These patients, representing a diverse group with HFrEF, HFmrEF, and HFpEF, were compared to a propensity score-matched external control group of 75 patients who received standard HF therapy without vericiguat during the same period. The study's design, including patients with various heart failure subtypes, broadens the scope of its findings beyond just...
- 28 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1607362
Open AccessEditorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings
Heart failure with reduced ejection fraction (HFrEF) remains a significant global health concern, characterized by high rates of morbidity, mortality, and frequent hospitalizations. Despite substantial progress in medical therapies over the past decades, the clinical course of HFrEF is often progressive, necessitating continuous research into novel and refined therapeutic strategies to improve patient outcomes. The management of HFrEF is a dynamic field, with clinical practice guidelines undergoing regular updates to incorporate the latest evidence and emerging treatment approaches. This constant evolution underscores the importance of ongoing investigation and the need for healthcare professionals to remain informed about the newest advancements in this area. The research topic "Advanced Therapeutic Strategies and Safety Profiles in Heart Failure with Reduced Ejection Fraction," published in Frontiers in Pharmacology, serves as a valuable platform for the dissemination of cutting-edge research focused on enhancing the treatment and safety profiles for individuals living with HFrEF. This topic encompasses a wide range of investigations, including the application of artificial intelligence and machine learning for predicting therapeutic outcomes, detailed evaluations of drug efficacy and safety across diverse patient populations, comparative studies of different treatment strategies, clinical trials exploring novel pharmacological agents, and the integration of advanced diagnostic tools to personalize treatment responses. This editorial aims to critically analyze and contextualize three specific studies recently published within this research topic, integrating their findings with the current understanding of HFrEF management up to the year 2025.By examining these recent contributions, this editorial seeks to provide an expert perspective on their significance and potential impact on the evolving landscape of HFrEF therapy.The cornerstone of contemporary HFrEF management lies in the implementation of guideline-directed medical therapy (GDMT), which has demonstrably improved survival and reduced hospitalizations (Heidenreich et al., 2022;Carrizales-Sepúlveda et al., 2024;Beghini et al., 2025). This foundational approach is built upon the synergistic effects of four main classes of medications: Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), which are often preferred as first-line renin-angiotensin system inhibitors due to their superior efficacy compared to ACE inhibitors or angiotensin receptor blockers; betablockers, which play a crucial role in mitigating the detrimental effects of the sympathetic nervous system; mineralocorticoid receptor antagonists (MRAs), which help to counteract the effects of aldosterone; and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is), which have emerged as a transformative therapy demonstrating significant benefits in reducing heart failure hospitalizations and cardiovascular mortality across a broad range of patients with and without diabetes. Current guidelines increasingly emphasize the importance of initiating and rapidly up-titrating these four foundational therapies to their maximally tolerated doses within the first few months following diagnosis to achieve optimal clinical outcomes. Major guideline updates, such as the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure and the 2023 ESC Focused Update of the 2021 ESC Guidelines, have further refined the recommendations for HFrEF management (Heidenreich et al., 2022). Notably, these updates highlight the expanded role of SGLT2 inhibitors across the entire spectrum of left ventricular ejection fraction, signifying a significant shift in the therapeutic paradigm (Carrizales-Sepúlveda et al., 2024).Beyond these foundational therapies, other emerging strategies and considerations have gained prominence in the management of HFrEF up to 2025 (Beghini et al., 2025).Vericiguat, an oral soluble guanylate cyclase stimulator, is recommended for consideration in patients with worsening HFrEF despite optimal GDMT, based on the findings of the VICTORIA trial (PW et al., 2020). Intravenous iron supplementation is increasingly recognized for its benefits in symptomatic patients with HFrEF and iron deficiency, improving symptoms and quality of life and potentially reducing heart failure hospitalizations (Beghini et al., 2025). Furthermore, the integration of palliative care into the management of advanced heart failure is gaining increasing recognition as a crucial component for improving patient quality of life and addressing their individual goals of care (Carrizales-Sepúlveda et al., 2024). The 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction further reinforces the central role of the "four pillars" of GDMT, emphasizing the preferred use of ARNIs as the initial renin-angiotensin system inhibitor in eligible patients. In this updated pathway, ACE inhibitors and angiotensin receptor blockers are primarily considered in patients who have contraindications, intolerance, or limited access to ARNIs (Maddox et al., 2024).Within the Frontiers in pharmacology, three recent studies offer valuable insights into advanced therapeutic strategies and safety profiles in HFrEF. Study 1: Vericiguat in Post-Acute Heart Failure (Li et al., 2025). This retrospective, singlecenter study sought to evaluate the safety and efficacy of vericiguat in 100 patients hospitalized for acute heart failure (HF) who were subsequently followed up as outpatients for a median of 68 days (Li et al., 2025). These patients, representing a diverse group with HFrEF, HFmrEF, and HFpEF, were compared to a propensity score-matched external control group of 75 patients who received standard HF therapy without vericiguat during the same period. The study's design, including patients with various heart failure subtypes, broadens the scope of its findings beyond just...
- Open Access
- 4 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 704-720
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
- 4 May 2023
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 32, 704-720
Open AccessSilencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis